Clinical stage focus Marin Biologic specializes in cell based assays and immunoassays for biotech and pharmaceutical companies in Phase I/II or Phase III stages, indicating a target for CRO partnerships in mid to late clinical development.

FDA cGMP GLP Compliance with US FDA cGMP/GLP and ICH standards across appropriate clinical development levels signals reliability and a strong framework to support regulated testing and submission workflows.

Experienced leadership Founded by a woman PhD and now led by CEO Tania Weiss with VP Science Peter Ralph, the leadership demonstrates endurance, scientific credibility, and potential for strategic collaborations and client trust.

Geographic niche Located in Novato, California between San Francisco and key wine regions, Marin Biologic is positioned to engage biotech clusters in Northern California and leverage regional networking for partnerships.

Growth potential With a revenue range of 10-25 million and a mid-sized team, Marin Biologic presents an attractive target for larger CROs seeking specialized cell assay and immunoassay capabilities or for pharma sponsors needing flexible, phase-appropriate testing support.